Market capitalization | $65.82m |
Enterprise Value | $20.39m |
EV/FCF (TTM) EV/FCF | negative |
Short interest | 2.30% |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Odonate Therapeutics, Inc. forecast:
3 Analysts have issued a Odonate Therapeutics, Inc. forecast:
Dec '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.02 -0.02 |
94%
94%
|
|
EBITDA | -0.80 -0.80 |
78%
78%
|
EBIT (Operating Income) EBIT | -0.82 -0.82 |
79%
79%
|
Net Profit | 7.33 7.33 |
83%
83%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Kevin Tang |
Founded | 2013 |
Website | www.odonate.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.